Takeda Shire Cooperation Agreement

When two or more persons, on the basis of a formal or informal agreement, act together to acquire or control a stake in relevant securities of an offering company or a securities supplier, they are considered to be a single person within the meaning of Rule 8.3. About Takeda Pharmaceutical Company Takeda Pharmaceutical Company Limited (TSE: 4502) is a global research and development-oriented pharmaceutical company committed to improving health and a better future for patients by translating science into life-changing drugs. Takeda focuses its research and development efforts on oncology, gastroenterological and neuroscientific therapies as well as vaccines. Takeda conducts research and development both internally and with partners to stay on the cutting edge of innovation. Innovative products, particularly in oncology and gastroenterology, as well as Takeda`s presence in emerging countries are currently fuelling Takeda`s growth. Approximately 30,000 Takeda employees are committed to improving the quality of life for patients and collaborate with Takeda`s healthcare partners in more than 70 countries. For more information, see www.takeda.com/newsroom/. Publication on the website In accordance with Rule 26.1 of the Code, a copy of this notice (subject to certain restrictions on persons residing in restricted jurisdictions) will be made available on Takeda`s website in www.takeda.com/investors/offer-for-shire no later than 12:00 p.m. (London time) on the business day following the date of this announcement. The content of the website mentioned in this notice is not part of this ad and is not part of this announcement.

Takeda (Investor Relations) Takashi Okubotakeda.ir.contact@takeda.com-81 3 3278 2306 Tsuyoshi TadaTsuyoshi.Tada@takeda.com 1 617 551 2933 In accordance with the rule 26 of the City Code on Takeovers and Mergers publishes a copy of the JBIC loan on Takeda`s website and can be accessed by www.takeda.com/investors/offer-for-shire no later than 12:00 p.m. (London time) on the business day following the announcement. Please note that the acquisition remains subject to certain conditions, including the agreement of the shareholders of both companies. Takeda (Media – Japan) Kazumi Kobayashikazumi.kobayashi@takeda.com-81 3 3278 2095 Takeda (Media – outside Japan) Elissa JohnsenElissa.Johnsen@takeda.com 1 312 285 3203 . “Working with first-class partners in drug discovery such as Evotec is critical to our model of transformative drug discovery and development,” says Steve Hitchcock, Global Head of Research at Takeda. “Takeda has been working with Evotec for a long time and is confident in Evotec`s capabilities.” Takeda retains the Shire intestinal disease drug, since the EU has waived the requirements of the agreement the shares have fallen by about 20% since the first confirmation of the agreement in April, but rose 2% on Tuesday, after the closure of the agreement was confirmed in a statement. . . . Takeda said the acquisition offers an increased geographic presence and position in Japan and the United States.

The company will be able to supply about 80 countries or regions. The company`s research and development focuses on oncology, gastroenterology (IG), neuroscience and rare diseases, as well as plasma-derived therapies (PDT) and vaccines. . While Japan`s Fair Trade Commission approved the agreement last October, the British court sanctioned it on 3 January this year. Takeda shareholders agreed to the deal last month. Takeda Pharmaceutical, headquartered in Japan, has officially completed the acquisition of Shire`s British staff for a total of $62 billion. Takeda is one of the ten largest pharmaceutical companies in the world. .

As part of this agreement, Sanofi has paid 60 million euros in advance and will contribute more resources to further development.